CN105029420A - Maca moringa tablet - Google Patents
Maca moringa tablet Download PDFInfo
- Publication number
- CN105029420A CN105029420A CN201510559391.5A CN201510559391A CN105029420A CN 105029420 A CN105029420 A CN 105029420A CN 201510559391 A CN201510559391 A CN 201510559391A CN 105029420 A CN105029420 A CN 105029420A
- Authority
- CN
- China
- Prior art keywords
- moringa
- maca
- parts
- agate coffee
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 235000011347 Moringa oleifera Nutrition 0.000 title claims abstract description 36
- 240000000759 Lepidium meyenii Species 0.000 title abstract description 7
- 235000000421 Lepidium meyenii Nutrition 0.000 title abstract description 7
- 235000012902 lepidium meyenii Nutrition 0.000 title abstract description 7
- 244000179886 Moringa oleifera Species 0.000 title description 28
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 48
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 8
- 239000000377 silicon dioxide Substances 0.000 claims abstract description 8
- 241000220215 Moringa Species 0.000 claims abstract 8
- VMYXUZSZMNBRCN-UHFFFAOYSA-N α-curcumene Chemical compound CC(C)=CCCC(C)C1=CC=C(C)C=C1 VMYXUZSZMNBRCN-UHFFFAOYSA-N 0.000 claims description 10
- 239000003755 preservative agent Substances 0.000 claims description 9
- 230000002335 preservative effect Effects 0.000 claims description 9
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 claims description 7
- HJTVQHVGMGKONQ-LUZURFALSA-N Curcumin II Natural products C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=CC(O)=CC=2)=C1 HJTVQHVGMGKONQ-LUZURFALSA-N 0.000 claims description 6
- UEPVWRDHSPMIAZ-IZTHOABVSA-N (1e,4z,6e)-5-hydroxy-7-(4-hydroxy-3-methoxyphenyl)-1-(4-hydroxyphenyl)hepta-1,4,6-trien-3-one Chemical compound C1=C(O)C(OC)=CC(\C=C\C(\O)=C\C(=O)\C=C\C=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-IZTHOABVSA-N 0.000 claims description 5
- VMYXUZSZMNBRCN-AWEZNQCLSA-N Curcumene Natural products CC(C)=CCC[C@H](C)C1=CC=C(C)C=C1 VMYXUZSZMNBRCN-AWEZNQCLSA-N 0.000 claims description 5
- 229930016183 alpha-curcumene Natural products 0.000 claims description 5
- NMRUIRRIQNAQEB-UHFFFAOYSA-N demethoxycurcumin Natural products OC(=CC(C=CC1=CC(=C(C=C1)O)OC)=O)C=CC1=CC=C(C=C1)O NMRUIRRIQNAQEB-UHFFFAOYSA-N 0.000 claims description 5
- UEPVWRDHSPMIAZ-UHFFFAOYSA-N p-hydroxycinnamoyl feruloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(O)=CC(=O)C=CC=2C=CC(O)=CC=2)=C1 UEPVWRDHSPMIAZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 abstract description 3
- 239000011707 mineral Substances 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 150000001413 amino acids Chemical class 0.000 abstract description 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 230000000050 nutritive effect Effects 0.000 abstract description 2
- 239000011782 vitamin Substances 0.000 abstract description 2
- 229930003231 vitamin Natural products 0.000 abstract description 2
- 235000013343 vitamin Nutrition 0.000 abstract description 2
- 229940088594 vitamin Drugs 0.000 abstract description 2
- 229920001661 Chitosan Polymers 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000036039 immunity Effects 0.000 abstract 1
- 230000036299 sexual function Effects 0.000 abstract 1
- 235000012239 silicon dioxide Nutrition 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 8
- 239000000203 mixture Substances 0.000 description 6
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 3
- 206010016256 fatigue Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000554155 Andes Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- MDKCFLQDBWCQCV-UHFFFAOYSA-N benzyl isothiocyanate Chemical compound S=C=NCC1=CC=CC=C1 MDKCFLQDBWCQCV-UHFFFAOYSA-N 0.000 description 2
- 235000012754 curcumin Nutrition 0.000 description 2
- 229940109262 curcumin Drugs 0.000 description 2
- 239000004148 curcumin Substances 0.000 description 2
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 229920001206 natural gum Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 208000012201 sexual and gender identity disease Diseases 0.000 description 2
- 208000015891 sexual disease Diseases 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007027 Calculus urinary Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000019229 Dinia Species 0.000 description 1
- 206010014020 Ear pain Diseases 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- QAADZYUXQLUXFX-UHFFFAOYSA-N N-phenylmethylthioformamide Natural products S=CNCC1=CC=CC=C1 QAADZYUXQLUXFX-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000007443 Neurasthenia Diseases 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 240000001970 Raphanus sativus var. sativus Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010047623 Vitamin C deficiency Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000003058 alpha-curcumene group Chemical group 0.000 description 1
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 1
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 208000007176 earache Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 125000004383 glucosinolate group Chemical group 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 206010019847 hepatosplenomegaly Diseases 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 201000005630 leukorrhea Diseases 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 229960004488 linolenic acid Drugs 0.000 description 1
- KQQKGWQCNNTQJW-UHFFFAOYSA-N linolenic acid Natural products CC=CCCC=CCC=CCCCCCCCC(O)=O KQQKGWQCNNTQJW-UHFFFAOYSA-N 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000012009 microbiological test Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000862 numbness Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000003899 penis Anatomy 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
- 208000010233 scurvy Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229910052712 strontium Inorganic materials 0.000 description 1
- CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 208000008281 urolithiasis Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 206010046901 vaginal discharge Diseases 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The invention discloses a maca moringa tablet. The maca moringa tablet comprises, by weight, 50-70 parts of maca, 20-40 parts of moringa, 2-8 parts of microcrystalline cellulose, 0.5-2.5 parts of silicon dioxide and 1-5 parts of chitosan. The maca moringa tablet has several kinds of rich mineral substances, vitamins, amino acid, antioxidants and natural anti-inflammatory bodies, has great nutritive value, can improve immunity, resists to fatigue, strengthens vigor and physical power and improves the sexual function of males.
Description
Technical field
The present invention relates to a kind of Maca tablet, particularly relate to a kind of agate coffee Moringa sheet.
Background technology
Agate coffee, formal name used at school: LepidiummeyeniiWalp, Spanish: Maca.Mainly producing in South America Andes and Chinese yunnan Lijing, is a kind of crucifer.Leaf is oval, and rhizome likeness in form turnip radish, edible is a kind of natural food, and nutrition is enriched, and has the reputation of " South America ginseng ".The hypocotyl of agate coffee may be golden or faint yellow, red, purple, blueness, black or green.Flaxen the most common, and shape, taste are also best.Agate coffee is rich in high unit nutrient, human body is had to the function of nourishing and fit keeping function.
Agate coffee originates in High aititude mountain area, is suitable for growing in High aititude, low latitudes, high day and night temperature, subacidity sandy loam, sun-drenched soil; Plantation area is mainly distributed in Andes, state, South America, and the Yulong Xueshan area of Chinese yunnan Lijing, and there is suitable kind of soil of larger area this two large main producing region.And also there is a small amount of plantation in other areas of Chinese yunnan and the area such as Xinjiang, Tibet.
Italian scientist DiniA has systematically drawn the chemical composition composition in the dry root of agate card first in 1994: protein content is more than 10% (protein content of the agate card kind of Hu Ning lakeside is more than 14%), the carbohydrate of 59%; The fiber of 8.5%, include the mineral matters such as abundant zinc, calcium, iron, titanium, rubidium, potassium, sodium, copper, manganese, magnesium, strontium, phosphorus, iodine, and containing vitamin C, B1, B2, B6, A, E, B12, B5, fat content is not high but mostly wherein be unrighted acid, the content of linoleic acid plus linolenic acid reaches more than 53%, and natural activity composition comprises alkaloid, glucosinolate and catabolite benzyl isothiocyanate, sterol, polyphenols etc.1999, American scientist has found vegetable active composition new containing two classes in agate card, macamides (macamides) He Maka rare (macaenes), and determine that these two kinds of materials have remarkable effect to balanced human's hormone secretion, the natural hormone engine so agate card is otherwise known as.In the specific aim research of agate card product, find again several special agate card alkaloid, along with going deep into of research, also had the activated novel substance of more tool in agate card and be isolated and identified.The Ministry of Public Health is national new resource food at approval agate coffee in 2011.
At present, the deep processed product of agate coffee is actually rare.
Summary of the invention
For the deficiencies in the prior art, technical problem to be solved by this invention is to provide a kind of agate coffee Moringa sheet.
For achieving the above object, the technology used in the present invention solution is:
A kind of agate coffee Moringa sheet, comprises following weight parts raw material: agate coffee 50-70 part, Moringa 20-40 part, microcrystalline cellulose 2-8 part, silica 0.5-2.5 part, chitosan oligosaccharide 1-5 part.
A kind of agate coffee Moringa sheet, is made up of following weight parts raw material: agate coffee 50-70 part, Moringa 20-40 part, microcrystalline cellulose 2-8 part, silica 0.5-2.5 part, chitosan oligosaccharide 1-5 part, biological preservative 0.2-0.6 part.
Described biological preservative is α-curcumene and/or Demethoxycurcumin.
Described biological preservative is made up of the α-curcumene of 40-60wt% and the Demethoxycurcumin of 40-60wt%.
By agate coffee, leaf of Moringa drying and crushing to 400-800 order, then mix with microcrystalline cellulose, silica, chitosan oligosaccharide and biological preservative, conventional common process compressing tablet, can obtain agate coffee Moringa sheet of the present invention.
Concrete, in the present invention:
Moringa, Moringa, also known as drumstick tree (Drumsticktree), originate in north India, there will be a known more than ten kind of kind in the world, originate in India, also there is a large amount of plantation in present China, be also called drumstick tree, it is perennial tropical deciduous tree, about there are 14 kinds in the whole world, comparatively normal edible kind has following three kinds at present: India's tradition Moringa (MoringaoleiferaLam.), India's improvement kind of Moringa (improvement kind of T.N. agriculture university of India, early give birth to and tool high pod yield) and African Moringa (former originates near Kenya's Turkana Lake and Ethiopia west and south).Moringa tree is used to carry out in treatment country in tradition, all knowing at original producton location north India and African resident utilizes Moringa to set as nutriment and treatment some diseases, root, skin, leaf, the flower of Moringa tree, really, seed, natural gum etc. are all pharmaceutically acceptable, can be described as the country such as India, Africa to cure the disease, the treasured of health care.Root has the effect of dampness removing, invigorating the spleen: control poor appetite, urolithiasis.Root or root skin have the effect of wind dispelling, anti-inflammatory, stomach invigorating, diuresis, establishing-Yang: control headache, dizzy, asthma, stomatitis, sphagitis, aerogastria, gastrointestinal convulsion, neurasthenia, hypertension, diabetes, scurvy, athlete's foot, skin disease, purulence ulcer and various cancer.Leaf is gynecological drug.Control uterus inflammation, red leukorrhea, gonorrhoea, syphilis.Leaf has dehumidifying, dispelling cold, the effect of establishing-Yang, diuresis, detumescence.Pod has the effect of dampness removing, strengthening the spleen and stomach.Control hepatopathy, arthralgia, hand and foot numbness.Seed controls hepatosplenomegaly.Natural gum controls dentary subcutaneous ulcer, otalgia.Preferred leaf of Moringa in the present invention.
α-curcumene, No. CAS: 644-30-4.Demethoxycurcumin, No. CAS: 24939-17-1.Curcumin, No. CAS: 458-37-7.
Agate coffee Moringa sheet of the present invention, is rich in several mineral materials, vitamin, amino acid, antioxygen element, naturally anti-scorching body, has higher nutritive value, can develop immunitypty, to antifatigue, strengthens energy, muscle power, raising male's sexual.After interpolation biological preservative, the shelf-life is significantly extended.
Detailed description of the invention
Below in conjunction with embodiment, the present invention is described further.Everyly do not depart from the present invention program's content, any simple modification done following examples according to technical spirit of the present invention or equivalent variations, all drop in protection scope of the present invention.
Embodiment 1-6:
By agate coffee and leaf of Moringa drying and crushing to 600 order, then mix with microcrystalline cellulose, silica, chitosan oligosaccharide and biological preservative, conventional common process compressing tablet, can obtain agate coffee Moringa sheet of the present invention.
Table 1: agate coffee Moringa slice prescription list position: gram
| Raw material | Embodiment 1 | Embodiment 2 | Embodiment 3 | Embodiment 4 | Embodiment 5 | Embodiment 6 |
| Agate coffee | 60 | 60 | 60 | 60 | 60 | 60 |
| Leaf of Moringa | 30 | 30 | 30 | 30 | 30 | 30 |
| Microcrystalline cellulose | 5 | 5 | 5 | 5 | 5 | 5 |
| Silica | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 |
| Chitosan oligosaccharide | 3 | 3 | 3 | 3 | 3 | 3 |
| α-curcumene | 0.2 | 0.4 | - | - | - | 0.2 |
| Demethoxycurcumin | 0.2 | - | 0.4 | - | - | - |
| Curcumin | - | - | - | - | 0.4 | 0.2 |
Test case 1:
The clinical drug curative effect of the embodiment of the present invention 1:
One, diagnostic criteria:
Contained according to " Diagnostics of Chinese Medicine ": male sexual disorder, immunologic hypofunction, lassitude, the disease Signs such as to be short of physical strength are as clinical criteria.
Male sexual disorder:
Impotence, premature ejaculation, penis anorthosis or suddenly and not hard, life quality is low.Soreness and weakness of waist and knees, insomnia and dreamful sleep, red tongue body, few tongue, stringy,thready and rapid pulse.
Immunologic hypofunction:
Cold-evil, the stasis of blood are stagnant, easy catching a cold, urinate red.Pale tongue, tongue thin, floating pulse, soft carefully unable in vain.Lassitude, to be short of physical strength: arteries and veins soft carefully unable, pale tongue, thin, tiredness, deficient in energy.Belong to " inferior health " state.
Immunologic hypofunction, has a delicate constitution, the insomnia disease that Dengs.
Two, inclusive criteria:
The above-mentioned standard of all genus all can be included in clinical.
Three, instructions of taking, consumption:
Oral: every day 2 times.Consumption: each serving with 2 grams.Every 30 days is a course for the treatment of.
Four, curative effect judging standard:
Signs performance according to diagnostic criteria:
Take without relapse indications after 1 year, belong to and curing.
Have after taking a course for the treatment of and obviously alleviate or remove symptom more than 70% person, belong to effective.
Have after taking 1-2 the course for the treatment of and alleviate or eliminate symptom more than 50% person, belong to effectively.
More than a course for the treatment of without alleviating and eliminating symptom, invalid.
Five, clinical effectiveness statistics:
In clinical at 100, wherein: sex dysfunction patient 50 people; A course for the treatment of cures 7 people; Two courses for the treatment of cure 42 people; Three the course for the treatment of effective 1 people.
Immunologic hypofunction: 25 people, one the course for the treatment of effective 11 people; Two courses for the treatment of cure 14 people.
Lassitude, be short of physical strength (" inferior health " state) 25 people; A course for the treatment of cures 18 people; Two courses for the treatment of cure 7 people.
Test case 3:
By the agate coffee Moringa sheet of embodiment 1-6, be placed in 28 DEG C, preservation half a year under relative humidity 85% environment, adopt " GB/T4789.2-2010 microbiological test of food hygiene total plate count mensuration " to carry out total plate count test.Concrete test result, in table 3.
Table 3: total plate count test chart
| Total plate count, cfu/g | |
| Embodiment 1 | 1.8×10 4 |
| Embodiment 2 | 2.6×10 4 |
| Embodiment 3 | 3.5×10 4 |
| Embodiment 4 | 3.2×10 5 |
| Embodiment 5 | 4.9×10 4 |
| Embodiment 6 | 3.8×10 4 |
After interpolation biological preservative, total plate count obviously declines, and shelf life of products is significantly extended.
Claims (2)
1. an agate coffee Moringa sheet, is characterized in that, is made up of following weight parts raw material: agate coffee 50-70 part, Moringa 20-40 part, microcrystalline cellulose 2-8 part, silica 0.5-2.5 part, chitosan oligosaccharide 1-5 part.
2. an agate coffee Moringa sheet, is characterized in that, is made up of following weight parts raw material: agate coffee 50-70 part, Moringa 20-40 part, microcrystalline cellulose 2-8 part, silica 0.5-2.5 part, chitosan oligosaccharide 1-5 part, biological preservative 0.2-0.6 part;
Described biological preservative is made up of 40-60wt% α-curcumene and 40-60wt% Demethoxycurcumin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510559391.5A CN105029420A (en) | 2015-09-02 | 2015-09-02 | Maca moringa tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510559391.5A CN105029420A (en) | 2015-09-02 | 2015-09-02 | Maca moringa tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105029420A true CN105029420A (en) | 2015-11-11 |
Family
ID=54436870
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510559391.5A Withdrawn CN105029420A (en) | 2015-09-02 | 2015-09-02 | Maca moringa tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105029420A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106262834A (en) * | 2016-08-15 | 2017-01-04 | 陈丽丹 | A kind of black hair health preserving health-care food and preparation method thereof |
| CN108056465A (en) * | 2017-12-29 | 2018-05-22 | 贺州市星辉科技有限公司 | A kind of antifatigue chewable tablets and preparation method thereof |
| CN108485878A (en) * | 2018-02-13 | 2018-09-04 | 吴建民 | A kind of SOD white wine and preparation method thereof with health maintenance effect |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013149323A1 (en) * | 2012-04-02 | 2013-10-10 | Ntegrity | Natural products for skin care |
| CN103750329A (en) * | 2014-02-18 | 2014-04-30 | 云南众爱生物科技有限公司 | Buccal tablet comprising ginseng, maca and horseradish tree leaf and preparation method of buccal tablet |
| CN104305202A (en) * | 2014-11-06 | 2015-01-28 | 河北考力森生物科技有限公司 | Ultrafine moringa oleifera powder compressed buccal tablet, and preparation method thereof |
| CN104824513A (en) * | 2015-05-26 | 2015-08-12 | 云南和融生物科技有限公司 | Maca moringa oleifera tablets and preparation method thereof |
-
2015
- 2015-09-02 CN CN201510559391.5A patent/CN105029420A/en not_active Withdrawn
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013149323A1 (en) * | 2012-04-02 | 2013-10-10 | Ntegrity | Natural products for skin care |
| CN103750329A (en) * | 2014-02-18 | 2014-04-30 | 云南众爱生物科技有限公司 | Buccal tablet comprising ginseng, maca and horseradish tree leaf and preparation method of buccal tablet |
| CN104305202A (en) * | 2014-11-06 | 2015-01-28 | 河北考力森生物科技有限公司 | Ultrafine moringa oleifera powder compressed buccal tablet, and preparation method thereof |
| CN104824513A (en) * | 2015-05-26 | 2015-08-12 | 云南和融生物科技有限公司 | Maca moringa oleifera tablets and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 齐莉莉等: "姜黄提取物的抗氧化及抗菌活性研究", 《中国调味品》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106262834A (en) * | 2016-08-15 | 2017-01-04 | 陈丽丹 | A kind of black hair health preserving health-care food and preparation method thereof |
| CN108056465A (en) * | 2017-12-29 | 2018-05-22 | 贺州市星辉科技有限公司 | A kind of antifatigue chewable tablets and preparation method thereof |
| CN108485878A (en) * | 2018-02-13 | 2018-09-04 | 吴建民 | A kind of SOD white wine and preparation method thereof with health maintenance effect |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101090284B1 (en) | Tonic comprising red ginseng and deer antlers extracts and manufacturing method thereof | |
| CN104856035A (en) | Health-care product for recuperating specific intrinsic constitution | |
| JP2014530905A (en) | Wrapping fermentation method using medicinal flowers and skin external preparation composition using the method | |
| KR101787432B1 (en) | Method for manufacturing oriental medicine composition which improves menorrhagia and dysmenorrhea comprising fermented velvet antler and yeast hydrolysate | |
| CN105695258A (en) | Female health wine containing lychee seed saponin | |
| CN102940153A (en) | Poultry feed for improving meat quality and egg quality | |
| CN104304548A (en) | Cold-preventing tea and preparation method thereof | |
| CN106937741A (en) | A kind of degreasing linseed meal cancer-resisting health slimming method and preparation method thereof | |
| KR101632794B1 (en) | METHOD OF MANUFACTURING PILL COMPRISED OF Protaetia brevitarsis seulensis | |
| CN103652926A (en) | Food composition for tumor patients | |
| CN108813501B (en) | Health-preserving honey paste with functions of clearing heat, moistening lung, relieving cough, reducing phlegm, relieving asthma and regulating human body functions | |
| JP2016077283A (en) | Fermented zen food composition comprising mixture of agricultural product and cereal mycelium, for preventing cancer and diabetes and for enhancing immunity, and production method thereof | |
| CN105029420A (en) | Maca moringa tablet | |
| CN104873826A (en) | Tea drink capable of clearing away lung heat and dispelling damp and preparation method thereof | |
| KR20160147424A (en) | An enzyme composition for treating metabolic disorders including extracts wasong | |
| CN105028845A (en) | Maca health protection tea | |
| CN104430720A (en) | Method for making functional biscuits through okra, fungus and algae plant mixtures | |
| CN104397717A (en) | Healthy anti-constipation corn weight-losing food and making method thereof | |
| CN101396056B (en) | Pine-needle tuckahoe teat and preparation method thereof | |
| CN104187246A (en) | Functional brown sugar and preparation method thereof | |
| CN105105120A (en) | Maca healthcare product | |
| CN114748583A (en) | Traditional Chinese medicine liquor for nourishing and preserving health | |
| CN105077418A (en) | Maca soup and preparation method thereof | |
| CN112500955A (en) | A distiller's yeast with Bayanxiang as main material and its preparation method | |
| CN104524180A (en) | Maca compound tablet, and preparation method and applications thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20151111 |